InMed Prognostics, a leader in AI-driven predictive analytics leveraging multi-modal data, including text, signal, and image, and the developer of a comprehensive automated organ-agnostic imaging platform, has recently announced its achievement of FDA 510(k) clearance for NeuroShield™. This groundbreaking tool/cloud platform utilizes AI, Deep Net, and 3D Convolutional Networks to offer neurologists and neuroradiologists a fully automated brain geometry-based quantifying analytics tool. 

NeuroShield employs 3D MR images, providing automated calculations of brain volumes to support physicians in crafting treatment plans for patients with neurodegenerative conditions such as Dementia, Alzheimer's Disease, Parkinson's, and Epilepsy. The segmentation analysis has demonstrated significant accuracy, reliability, and effectiveness of NeuroShield. Given that over a billion people worldwide are affected by neurodegenerative disorders, the timely identification of potential candidates for early intervention is pivotal to optimize the benefits of emerging pharmaceutical treatments. 

NeuroShield addresses this need by providing a tool for physicians to monitor and devise effective treatment strategies. Notably, it stands out as the world's first platform to offer reference ranges adaptable based on age, gender, and ethnicity, thereby setting new benchmarks in healthcare and advancing precision medicine. The company has consistently aimed to make state-of-the-art healthcare tools affordable, accessible, and reliable for everyone, globally.

Source: prnewswire.com